



This CD Laboratory focuses on understanding the molecular mechanisms behind chronic inflammatory skin diseases and how these mechanisms are influenced by specific therapies. The goal is to discover innovative treatment methods and identify biomarkers to predict therapy responses.

According to the WHO, chronic inflammation is a major health threat today. Psoriasis, for example, is not only a physically challenging condition but also carries significant social stigma. Beyond affecting the skin, psoriasis can also impact other organs, potentially leading to conditions like psoriatic arthritis or psoriatic spondylitis. Despite progress in targeted therapies, central inflammatory mechanisms remain under-explored. Gaining deeper insights into the cellular and molecular processes at play may open the door to new therapeutic possibilities.

A key area of focus in this research is tissue-resident memory T cells (TRM) in the skin and subcutaneous fatty tissue. By using psoriasis as a model, the laboratory is investigating how these cells respond to biological therapies. This includes examining the cellular and molecular interactions in various tissue compartments.

- The research is driven by three primary goals:
- Identifying TRM in fatty tissue as a factor in chronic skin inflammation.
 - Visualizing molecular target structures on pathogenic T cells to inform new therapeutic strategies.
 - Characterizing molecular patterns that could serve as potential biomarkers for predicting therapy responses.

Overall, this laboratory is making a significant contribution to advancing our understanding of chronic inflammatory skin diseases and developing novel treatment strategies.

Please register by 22nd April 2025 at meduniwien.ac.at/hautkrankheiten



Jugendstilhösraum, Rektoratsgebäude (BT88), 2nd Floor
Medical University of Vienna
Spitalgasse 23, 1090 Vienna

Please be aware that photographs and/or video footage will be taken at the event. These may be used for the purpose of documenting or reporting the event and published in print and online media, on various social media platforms and on MedUni Vienna's website.



In Christian Doppler Laboratories, application-oriented basic research is pursued at a high level, and expert scientists cooperate with innovative companies. The **Christian Doppler Research Association** is an international best practice example for promoting this collaboration.



Christian Doppler Laboratories are financed jointly by the public purse and the participating companies. The most important public sponsor is the **Federal Ministry of Economy, Energy and Tourism (BMWET)**.



Johnson & Johnson is one of the world's leading life science companies, operating in the two segments Innovative Medicines (pharmaceutical division, formerly Janssen) and MedTech (medical technology division). With the aim of shaping the healthcare solutions of tomorrow, the company invests around 11 billion euros annually in research and development in the pharmaceutical division. Together with a broad network of partners and collaborations, J&J sees itself as a driver of medical innovations and therapeutic solutions in five focus areas: Immunology, Oncology, Neuroscience, Cardio-Pulmonology and Specific Ophthalmology. J&J Innovative Medicine Austria works with a team of over 150 employees to expand local research initiatives and promote early access to innovative medicines in Austria.



Opening CD Laboratory for Chronic Inflammatory Skin Diseases

Monday, 28th April 2025, 1.00 pm
Jugendstilhösraum, MedUni Vienna
Rektoratsgebäude, 2nd Floor
Spitalgasse 23, 1090 Vienna

meduniwien.ac.at/hautkrankheiten

Opening CD Laboratory for Chronic Inflammatory Skin Diseases

Monday, 28th April 2025

1.00 pm

Opening of the CD Laboratory for Chronic inflammatory Skin Diseases

Welcome

Michaela Fritz
Vice Rector for Research and Innovation,
MedUni Vienna

Sylvia Knapp
Member of the Senate of the Christian Doppler
Research Association

Presentation of the CD Laboratory for Chronic Inflammatory Skin Diseases

Georg Stary
Department of Dermatology, MedUni Vienna/University
Hospital Vienna, Center for Molecular Medicine (CeMM)

Sara Leitao
Managing Director Janssen-Cilag Pharma GmbH, a
Johnson & Johnson company

Moderation
Wolfgang Peter Weninger
Head of the Department of Dermatology,
MedUni Vienna/University Hospital Vienna

Get-together

2.30 – 6.30pm

Symposium on Chronic Inflammatory Skin Diseases

Introduction

Georg Stary, Department of Dermatology,
MedUni Vienna/University Hospital Vienna,
Center for Molecular Medicine (CeMM)

2.30 – 4.20 pm

Session I

- **Microenvironmental cues to persisting T cell memory formation in human skin**
Liv Eidsmo, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital
- **Psoriasis: molecular endotypes and treatment resistance**
Michel Gilliet, Department of Dermatology, CHUV University Hospital and University of Lausanne
- **Unexpected insights into inflammatory skin diseases**
Johannes Griss, Department of Dermatology, MedUni Vienna/University Hospital Vienna

4.20 – 4.40 pm

Break

4.40 – 6.30 pm

Session II

- **Human skin in development and disease**
Muzlifah Haniffa, Wellcome Sanger Institute and Newcastle University
- **T cell-mediated fibroblast reprogramming drives chronic granulomatous inflammation**
Aglaja Kopf, Department of Dermatology, MedUni Vienna/University Hospital Vienna, Center for Molecular Medicine (CeMM)
- **Tissue-resident memory T cells in chronic inflammation**
Johanna Strobl, Department of Dermatology, MedUni Vienna/University Hospital Vienna, Center for Molecular Medicine (CeMM)
- **How T cells recognize skin targets: from immune checkpoint inhibitor-mediated toxicity to inflammatory dermatoses**
Lukas Flatz, Department of Dermatology, University Hospital Tübingen

6.30 pm

Farewell